These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36812671)

  • 41. Percolation phenomenon: the effect of capillary network rarefaction.
    Hudetz AG
    Microvasc Res; 1993 Jan; 45(1):1-10. PubMed ID: 8479338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exercise Training Restores the Cardiac Microrna-16 Levels Preventing Microvascular Rarefaction in Obese Zucker Rats.
    Fernandes T; Casaes L; Soci Ú; Silveira A; Gomes J; Barretti D; Roque F; Oliveira E
    Obes Facts; 2018; 11(1):15-24. PubMed ID: 29402872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials.
    Pinxterhuis TH; Ploumen EH; Zocca P; Doggen CJM; Schotborgh CE; Anthonio RL; Roguin A; Danse PW; Benit E; Aminian A; Stoel MG; Linssen GCM; Geelkerken RH; von Birgelen C
    Atherosclerosis; 2022 Aug; 355():52-59. PubMed ID: 35641327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dexamethasone Does Not Inhibit Treadmill Training-Induced Angiogenesis in Myocardium: Role of MicroRNA-126 Pathway.
    Herrera NA; Duchatsch F; Tardelli LP; Dionísio TJ; Santos CF; Amaral SL
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):708-714. PubMed ID: 33105326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero.
    Pladys P; Sennlaub F; Brault S; Checchin D; Lahaie I; Lê NL; Bibeau K; Cambonie G; Abran D; Brochu M; Thibault G; Hardy P; Chemtob S; Nuyt AM
    Am J Physiol Regul Integr Comp Physiol; 2005 Dec; 289(6):R1580-8. PubMed ID: 16037123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis.
    Brevetti G; Piscione F; Silvestro A; Galasso G; Di Donato A; Oliva G; Scopacasa F; Chiariello M
    Thromb Haemost; 2003 Jun; 89(6):1058-63. PubMed ID: 12783119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease.
    Fakhry M; Sidhu MS; Bangalore S; Mathew RO
    Rev Cardiovasc Med; 2020 Jun; 21(2):157-162. PubMed ID: 32706205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary microcirculation and cardiovascular pathology.
    Garot P; Teiger E; Dupouy P; Aptecar E; Hittinger L; Dubois-Randé JL
    Drugs; 1999; 59 Spec No():23-31. PubMed ID: 10548389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microcirculatory rarefaction in South Asians - a potential mechanism for increased cardiovascular risk and diabetes.
    Hughes AD; Bathula R; Park C; Tillin T; Wit N; McG Thom S; Chaturvedi N
    PLoS One; 2013; 8(10):e76680. PubMed ID: 24116136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative assessment of coronary microvascular function in patients with and without epicardial atherosclerosis.
    Melikian N; Vercauteren S; Fearon WF; Cuisset T; MacCarthy PA; Davidavicius G; Aarnoudse W; Bartunek J; Vanderheyden M; Wyffels E; Wijns W; Heyndrickx GR; Pijls NH; de Bruyne B
    EuroIntervention; 2010 Apr; 5(8):939-45. PubMed ID: 20542779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.
    Menshikh A; Scarfe L; Delgado R; Finney C; Zhu Y; Yang H; de Caestecker MP
    Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1383-F1397. PubMed ID: 31509009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microvascular rarefaction and tissue vascular resistance in hypertension.
    Greene AS; Tonellato PJ; Lui J; Lombard JH; Cowley AW
    Am J Physiol; 1989 Jan; 256(1 Pt 2):H126-31. PubMed ID: 2912175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal vascular structure and rarefaction.
    Chade AR
    Compr Physiol; 2013 Apr; 3(2):817-31. PubMed ID: 23720331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell Type Dependent Suppression of Inflammatory Mediators by Myocardin Related Transcription Factors.
    Liu L; Bankell E; Rippe C; Morén B; Stenkula KG; Nilsson BO; Swärd K
    Front Physiol; 2021; 12():732564. PubMed ID: 34671275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage.
    Wang W; Li G; Ma J; Fan X; Lu J; Sun Q; Yao J; He Q
    Front Pharmacol; 2024; 15():1346905. PubMed ID: 38405666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study.
    Levin MG; Klarin D; Assimes TL; Freiberg MS; Ingelsson E; Lynch J; Natarajan P; O'Donnell C; Rader DJ; Tsao PS; Chang KM; Voight BF; Damrauer SM;
    JAMA Netw Open; 2021 Jan; 4(1):e2034461. PubMed ID: 33464320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?
    Schley G; Goppelt-Struebe M
    Kidney Int; 2022 Oct; 102(4):686-688. PubMed ID: 36150758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myocardial epigenetic modifications link chronic kidney disease to coronary microvascular disease.
    Sen P; Sorop O; Merkus D
    Am J Physiol Heart Circ Physiol; 2023 Jan; 324(1):H175-H176. PubMed ID: 36525479
    [No Abstract]   [Full Text] [Related]  

  • 59. Training counteracts DEX-induced microvascular rarefaction by improving the balance between apoptotic and angiogenic proteins.
    Jesus I; Herrera NA; Andreo JC; Santos CF; Amaral SL
    Steroids; 2020 Apr; 156():108573. PubMed ID: 31904375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design.
    Mohammedi K; Préaubert N; Cariou T; Rigalleau V; Foussard N; Piazza L; Bairras-Martin C; Couffinhal T; Bezin J; Benard A
    Cardiovasc Diabetol; 2021 Mar; 20(1):63. PubMed ID: 33714278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.